US · CDNA · MEDICAL - DIAGNOSTICS & RESEARCH
CareDx, Inc (CDNA) intrinsic value and stock valuation
$70.00as of 2026-11-21 · Mkt cap 2.35B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
CareDx, Inc DCF and intrinsic value
InvestorsCraft values CDNA with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from CDNA’s statements →
CareDx, Inc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $379.8M | $333.8M | $280.3M | $321.8M | $296.4M |
| Operating income | -$-25.07M | $40.8M | -$-203.36M | -$-77.23M | -$-29.73M |
| Net income | -$-21.35M | $52.6M | -$-190.28M | -$-76.61M | -$-30.66M |
| EPSd | -$-400.64K | $928.1K | -$-3.54M | -$-1.44M | -$-586.91K |
| Operating cash flow | $42M | $38.1M | -$-18.39M | -$-25.24M | -$-19.29M |
| Capital expenditure | -$-5.91M | -$-6.48M | -$-9.24M | -$-24.33M | -$-20.26M |
| Free cash flow | $36.1M | $31.6M | -$-27.63M | -$-49.57M | -$-39.55M |
| Total assets | $413.2M | $491.1M | $466.8M | $543M | $566.6M |
| Total debt | $26.2M | $28.4M | $34.2M | $39M | $21.4M |
| Net debt | -$-39.23M | -$-86.32M | -$-47.98M | -$-50.92M | -$-327.13M |
| Total equity | $303.1M | $378.4M | $261.3M | $430.9M | $465.9M |
| Cash and short-term investments | $177.2M | $260.7M | $235.4M | $293.1M | $348.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $379.8M | $333.8M | $280.3M | $321.8M | $296.4M |
| Cost of revenue | $123.2M | $109.6M | $102M | $112.2M | $97.4M |
| Gross profit | $256.6M | $224.2M | $178.3M | $209.6M | $199M |
| Research and development expenses | $71.4M | $72.4M | $81.9M | $90.4M | $76.5M |
| Selling, general and administrative expenses | $210.2M | $205.5M | $201.2M | $196.4M | $152.2M |
| Other expenses | $0.00 | -$-94.52M | $98.6M | $0.00 | $0.00 |
| Operating expenses | $281.6M | $183.4M | $381.7M | $286.8M | $228.7M |
| Cost and expenses | $404.9M | $293M | $483.7M | $399M | $326.1M |
| Interest income | $9.17M | $11.8M | $11.9M | $3.76M | $160K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $20.4M | $19.8M | $19.8M | $16M | $11.9M |
| Ebitda | -$-4.66M | -$-33.99M | -$-84.92M | -$-60.23M | -$-20.2M |
| Operating income | -$-25.07M | $40.8M | -$-203.36M | -$-77.23M | -$-29.73M |
| Total other income/expenses, net | $3.99M | $12.1M | $13.2M | $1M | -$-2.36M |
| Income before tax | -$-21.08M | $52.9M | -$-190.14M | -$-76.23M | -$-32.09M |
| Income tax expense | $270K | $310K | $140K | $380K | -$-1.43M |
| Net income | -$-21.35M | $52.6M | -$-190.28M | -$-76.61M | -$-30.66M |
| Weighted average shares outstanding | $53.3M | $52.8M | $53.8M | $53.3M | $52.2M |
| Weighted average diluted shares outstanding | $53.3M | $56.6M | $53.8M | $53.3M | $52.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $177.2M | $260.7M | $235.4M | $293.1M | $348.5M |
| Net receivables | $42.6M | $64.6M | $51.1M | $66.3M | $59.8M |
| Inventory | $26.7M | $19.5M | $19.5M | $19.2M | $17.2M |
| Total current assets | $257.1M | $351.8M | $313.7M | $387.9M | $433.4M |
| Property, plant and equipment, net | $55.7M | $57.9M | $65.1M | $70.2M | $40M |
| Goodwill and intangible assets | $72.3M | $78.5M | $86M | $80.6M | $87.2M |
| Long-term investments | $24.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $156.1M | $139.2M | $153.1M | $155.1M | $133.3M |
| Total assets | $413.2M | $491.1M | $466.8M | $543M | $566.6M |
| Accounts payable | $9.99M | $7.69M | $12.9M | $9.94M | $13.3M |
| Short-term debt | $6.51M | $6.1M | $5.94M | $5.59M | $3.96M |
| Deferred revenue | $4.65M | $4.85M | $4.75M | $5.34M | $4.21M |
| Total current liabilities | $89.9M | $89.4M | $78.1M | $76M | $77.3M |
| Long-term debt | $19.7M | $22.3M | $28.3M | $33.4M | $17.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $20.3M | $23.3M | $127.4M | $36.1M | $23.4M |
| Capital lease obligations | $26.2M | $28.4M | $34.2M | $39M | $21.4M |
| Total liabilities | $110.1M | $112.6M | $205.5M | $112.1M | $100.8M |
| Common stock | $50K | $50K | $50K | $50K | $50K |
| Retained earnings | -$-735.36M | -$-626.24M | -$-678.27M | -$-460.44M | -$-383.19M |
| Accumulated other comprehensive income (loss) | -$-5.51M | -$-8.57M | -$-6.96M | -$-7.5M | -$-4.67M |
| Total equity | $303.1M | $378.4M | $261.3M | $430.9M | $465.9M |
| Total investments | $135.9M | $146M | $153.2M | $203.2M | $0.00 |
| Total debt | $26.2M | $28.4M | $34.2M | $39M | $21.4M |
| Net debt | -$-39.23M | -$-86.32M | -$-47.98M | -$-50.92M | -$-327.13M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-21.35M | $52.6M | -$-190.28M | -$-76.61M | -$-30.66M |
| Depreciation and amortization | $20.4M | $19.8M | $19.8M | $16M | $11.9M |
| Stock-based compensation | $34.9M | $66.4M | $49.1M | $46.6M | $36.1M |
| Change in working capital | $3.81M | -$-102.31M | $106M | -$-14.22M | -$-40.97M |
| Accounts receivable | $22.5M | -$-13.74M | $16M | -$-6.66M | -$-24.42M |
| Inventory | -$-4.96M | -$-1.02M | $50K | -$-2.86M | -$-6.93M |
| Accounts payable | $810K | -$-5.11M | $2.9M | -$-2.05M | $1.79M |
| Net cash provided by operating activities | $42M | $38.1M | -$-18.39M | -$-25.24M | -$-19.29M |
| Investments in property, plant and equipment | -$-6.59M | -$-6.48M | -$-9.24M | -$-24.33M | -$-20.26M |
| Acquisitions, net | $0.00 | $0.00 | -$-6.68M | -$-610K | -$-15.43M |
| Net cash used for investing activities | $2.16M | -$-480K | $40.5M | -$-228.5M | $47.7M |
| Common stock issued | $8M | $0.00 | $0.00 | $0.00 | $188.9M |
| Common stock repurchased | -$-87.77M | -$-520K | -$-27.54M | -$-640K | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-93.39M | -$-5.61M | -$-29.61M | -$-4.54M | $185.6M |
| Net change in cash | -$-49.29M | $32.5M | -$-7.66M | -$-258.25M | $213.8M |
| Cash at end of period | $66M | $115.3M | $82.8M | $90.4M | $348.7M |
| Operating cash flow | $42M | $38.1M | -$-18.39M | -$-25.24M | -$-19.29M |
| Capital expenditure | -$-5.91M | -$-6.48M | -$-9.24M | -$-24.33M | -$-20.26M |
| Free cash flow | $36.1M | $31.6M | -$-27.63M | -$-49.57M | -$-39.55M |
Line items
Line items
Line items
About CareDx, Inc
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
- CEO
- John Walter Hanna Jr.
- Employees
- 765
- Beta
- 2.43
Explore
Frequently asked questions
What is the intrinsic value of CareDx, Inc (CDNA)?
CareDx, Inc (CDNA) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CDNA undervalued?
CDNA trades at a price of $70.00 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.